Open AccessLong‐term outcomes of patients with ulcerative proctitis: Analysis from a large referral centre cohort
Author(s) -
Dubois Evelyne,
Moens Annick,
Geelen Rob,
Sabino João,
Ferrante Marc,
Vermeire Séverine
Publication year - 2020
Publication title -
ueg journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.667
H-Index - 35
eISSN - 2050-6414
pISSN - 2050-6406
DOI - 10.1177/2050640620941345
Subject(s) - medicine , azathioprine , ulcerative colitis , interquartile range , refractory (planetary science) , proctitis , retrospective cohort study , cohort , infliximab , surgery , disease , physics , astrobiology
Long‐term outcomes of patients with ulcerative proctitis (UP) have been poorly investigated, since these patients are excluded from participation in randomized controlled clinical trials. Objective The aim of this study was to investigate the prognostic and therapeutic long‐term outcomes of patients with UP. Methods A retrospective study of patients with UP followed at our referral centre between 1 January 1998 and 1 January 2019 was performed. Treatment success was defined as clinical response (significant improvement in UP‐related symptoms) and endoscopic response (mayo endoscopic sub‐score of 0 or 1) if available at last follow‐up. Results From a total of 1561 patients with ulcerative colitis, 118 patients with UP were identified. A total of 36 (31%) patients were refractory to rectal and oral therapy with 5‐ASA and corticosteroids, necessitating azathioprine as monotherapy in 19 (16%) patients and/or biological therapies in 33 (28%) patients. After a median follow‐up of 71 months (interquartile range 29–149 months), treatment success was observed in 103/118 (87%) UP patients and in 25/36 (69%) patients with refractory UP. Clinical response rates were significantly higher for refractory UP patients treated with biologicals (23/33; 70%) compared to ones treated with azathioprine (2/19; 11%; p = 0.001). Conclusion Good clinical outcomes were recorded in UP, with treatment success in 87% of patients. Nevertheless, 28% needed escalation to biologicals. Long‐term outcome in patients on biologicals was superior to azathioprine.